Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26384841 | 0.96 | ALDH1A1 (0.54) | ALDH1A1NPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL23269699 | 0.92 | ALDH1A1 (0.51) | ALDH1A1NPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL17286057 | 0.85 | ALDH1A1 (0.45) | ALDH1A1NPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL15043685 | 0.84 | ALDH1A1 (0.59) | ALDH1A1NPC1LMNARAB9ADRD2 | |
| SCHEMBL16803394 | 0.83 | ALDH1A1 (0.42) | ALDH1A1NPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL19275359 | 0.83 | ALDH1A1 (0.54) | ALDH1A1NPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL20457594 | 0.83 | ALDH1A1 (0.58) | ALDH1A1NPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL12325467 | 0.83 | ALDH1A1 (0.58) | ALDH1A1NPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL17285967 | 0.82 | ALDH1A1 (0.46) | ALDH1A1NPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL8290941 | 0.82 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2DRD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3958867-B1 | SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2023250513-A1 | 13-MEMBERED MACROLIDE COMPOUNDS FOR TREATING DISEASES MEDIATED BY ABNORMAL PROTEIN TRANSLATION | ZIKANI THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023178299-A1 | PRODRUGS OF GANAXOLONE | MARINUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023093832-A1 | TRICYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海济煜医药科技有限公司 | 2023-06-01 | — | — | WO | disclosed |
| EP-3145929-B1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-13 | — | — | EP | disclosed |
| EP-3322706-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| WO-2018136661-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2017108723-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017091661-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | STROVEL JEFFREY WILLIAM (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-8013152-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010149684-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010106097-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | WO | disclosed |
| US-20100197667-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197667-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7728144-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728144-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2007039578-A1 | IMIDAZOLYL-SUBSTITUTED AZABENZOPHENONE COMPOUNDS | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039580-A1 | IMIDAZOLYL-SUBSTITUTED BENZOPHENONE COMPOUNDS | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039581-A1 | IMIDAZOLYL-SUBSTITUTED DIAZABENZOPHENONE COMPOUNDS | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197667-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM5 | ALDH1A1 1522/4885NPC1 2507/4885LMNA 2662/4885 |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | ALDH1A1 729/4885NPC1 2578/4885LMNA 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.